Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUWVGP)

Drug Name
MMDA Drug Info
Synonyms
MMDA; 5-Methoxy-3,4-methylenedioxyamphetamine; (+-)-MMDA; DEA No. 7401; 13674-05-0; 3-Methoxy-4,5-methylenedioxyphenylisopropylamine; Amphetamine, 3,4-methylenedioxy-5-methoxy; 3-Methoxy-alpha-methyl-4,5-methylenedioxyphenethylamine; BRN 1246630; Phenethylamine, alpha-methyl-3-methoxy-4,5-(methylenedioxy)-; 1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl-; 3-Methoxy-4,5-methylenedioxyamphetamine; beta-Methoxy-alpha-methyl-4,5-(methylenedioxy)phenethyl amine; Phenethylamine, 3-methoxy-alpha-methyl-4,5-(methylenedio
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
26175
CAS Number
CAS 13674-05-0
TTD Drug ID
DMUWVGP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Norepinephrine transporter (NET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [2]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [3]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [4]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [2]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [5]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [7]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [6]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [8]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [2]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [3]
Fluoxetine DM3PD2C Bipolar depression Approved [10]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [11]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [12]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [5]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [6]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [10]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [10]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [13]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [14]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [15]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [11]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [16]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [17]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [18]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [19]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [20]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Synaptic vesicle amine transporter (SLC18A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deutetrabenazine DMUPFLI Huntington disease 8A01.10 Approved [10]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [22]
Tetrabenazine DMYWQ0O Huntington disease 8A01.10 Approved [22]
Alseroxylon DMB47TQ Hypertension BA00-BA04 Approved [23]
Valbenazine Tosylate DMQSA2V Tardive dyskinesia 8A02.10 Approved [10]
Alkavervir DMB4HFI High blood pressure BA00 Approved [10]
Ingrezza DMVPLNC Tardive dyskinesia 8A02.10 Phase 4 [24]
NBI-98854 DMVO1C0 Movement disorder 8A07-8A0Z Phase 3 [25]
AV 133 DM0EQ9X Alzheimer disease 8A20 Phase 3 [26]
Lobeline DMT3KB4 Substance use disorder 6C4Z Phase 2 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [5]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [28]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [29]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [10]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [30]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [31]
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Attention deficit hyperactivity disorder 6A05.Z Approved [32]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [33]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [34]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [35]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [36]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [37]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [38]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [39]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [40]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [41]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [42]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [31]
Budipine DMODHQI Migraine 8A80 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [44]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [45]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [46]
Isocarboxazid DMAF1NB Depression 6A70-6A7Z Approved [47]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [48]
Psoralen DMIZJ8M N. A. N. A. Phase 3 [49]
CHF-3381 DMQ2O8V Neuropathic pain 8E43.0 Phase 2 [50]
Ladostigil DMJSY3Q Alzheimer disease 8A20 Phase 2 [51]
CX157 DMS2WB5 Mood disorder 6A60-6E23 Phase 2 [52]
PIPERINE DMYEAB1 Vitiligo ED63.0 Phase 1/2 [53]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [1]
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Modulator [1]
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Antagonist [1]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Antagonist [1]
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Modulator [1]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Modulator [1]
Synaptic vesicle amine transporter (SLC18A2) TTNZRI3 VMAT2_HUMAN Antagonist [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
3 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
4 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
5 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
6 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
7 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
9 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
12 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
13 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
14 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
15 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
16 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
17 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
19 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
20 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
21 Clinical pipeline report, company report or official report of Lundbeck.
22 Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
23 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
24 VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
25 NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
26 Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
27 Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
28 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
29 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
30 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
32 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
33 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
35 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
36 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
37 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
39 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
40 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
41 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
42 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
43 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
44 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
45 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
46 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
47 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
48 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
49 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
50 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
51 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
52 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
53 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.